Clinical Trial Update: CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating CART19 cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia and relapsed/refractory non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Or Refractory B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CART19 cells

Snippet

Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic | Conditions: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory | Phase 1 | Status: RECRUITING